Agios Pharmaceuticals, Inc. Stock price

Equities

AGIO

US00847X1046

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
29.24 USD +0.41% Intraday chart for Agios Pharmaceuticals, Inc. -3.31% +31.30%
Sales 2024 * 64.29M Sales 2025 * 115M Capitalization 1.64B
Net income 2024 * -317M Net income 2025 * -360M EV / Sales 2024 * 24.4 x
Net cash position 2024 * 68.82M Net Debt 2025 * 36.47M EV / Sales 2025 * 14.6 x
P/E ratio 2024 *
-5.33 x
P/E ratio 2025 *
-4.96 x
Employees 385
Yield 2024 *
-
Yield 2025 *
-
Free-Float 76.35%
More Fundamentals * Assessed data
Dynamic Chart
RBC Trims Price Target on Agios Pharmaceuticals to $42 From $43, Keeps Outperform Rating MT
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Agios Pharmaceuticals 2023 Loss Widens, Revenue Rises MT
Transcript : Agios Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Agios Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Agios Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM
Agios Pharmaceuticals Insider Sold Shares Worth $277,397, According to a Recent SEC Filing MT
Agios Pharmaceuticals, Inc. Announces Key Anticipated 2024 Milestones Across Rare Disease Portfolio CI
Agios Pharmaceuticals Shares Jump Pre-Bell as Phase 3 Study on Blood Disorder Treatment Meets Endpoints MT
Agios' blood disorder drug meets goals of late-stage study RE
Agios Pharmaceuticals, Inc. Announces Phase 3 Energize Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia CI
Transcript : Agios Pharmaceuticals, Inc. - Special Call
Transcript : Agios Pharmaceuticals, Inc. - Special Call
Agios Pharmaceuticals, Inc. Presents Positive Results from Phase 2 Portion of the Rise Up Pivotal Study in Sickle Cell Disease at 65Th ASH Annual Meeting and Exposition CI
Agios Pharmaceuticals, Inc. Announces Clinical Proof-Of-Concept in Phase 2A Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes CI
More news
1 day+0.41%
1 week-3.31%
Current month-9.53%
1 month-13.16%
3 months+28.30%
6 months+18.05%
Current year+31.30%
More quotes
1 week
28.57
Extreme 28.57
30.23
1 month
28.57
Extreme 28.57
33.04
Current year
20.96
Extreme 20.96
35.50
1 year
19.80
Extreme 19.795
35.50
3 years
16.75
Extreme 16.75
62.16
5 years
16.75
Extreme 16.75
68.89
10 years
16.75
Extreme 16.75
138.85
More quotes
Managers TitleAgeSince
Chief Executive Officer 55 22-08-07
Director of Finance/CFO 49 22-09-25
Chairman 62 17-12-04
Members of the board TitleAgeSince
Director/Board Member 69 23-05-31
Director/Board Member 64 14-12-08
Director/Board Member 71 15-06-22
More insiders
Date Price Change Volume
24-03-28 29.24 +0.41% 434,786
24-03-27 29.12 +0.21% 666,420
24-03-26 29.06 -2.09% 554,730
24-03-25 29.68 -0.67% 413,837
24-03-22 29.88 -1.19% 442,221

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a variety of mutant pyruvate kinase (PK) enzymes, for the treatment of hemolytic anemias. The Mitapivat is an orally available small molecule and a potent activator of the pyruvate kinase R (PKR) enzymes. In addition, it is also evaluating mitapivat for the treatment of alpha- and beta- thalassemia and sickle cell disease (SCD) in ongoing clinical trials. The Company is also developing AG-946, a clinical-stage oral activator of PKR enzymes for the treatment of hemolytic anemias and other indications, including SCD.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
29.24 USD
Average target price
40.67 USD
Spread / Average Target
+39.08%
Consensus
  1. Stock
  2. Equities
  3. Stock Agios Pharmaceuticals, Inc. - Nasdaq